

# Visionflex Group

ASX:VFX

## H1 FY25 Results Investor Presentation


21 FEBRUARY 2025

This announcement was approved for release by  
the Board of Directors.




# The Visionflex mission

Empowering health practitioners globally with cutting edge technologies to elevate patient outcomes.






Visionflex Group



Visionflex proprietary hardware and software connect a range of third-party medical devices to empower practitioners to deliver world class virtual care.

# Hardware

Visionflex hardware enables health practitioners to virtually conduct medical examinations with confidence and serves as a foundational step for establishing long term software subscriptions.

PERIPHERALS + SOFTWARE	DEVICE + PERIPHERALS + SOFTWARE	MEDICAL CART + PERIPHERALS + SOFTWARE
		
GEIS® Camera and peripheral devices integrated with Visionflex software, to deliver clinical consultations virtually.	Mobile solution, including tablet/laptop, GEIS® Camera and peripherals, integrated with Visionflex software, to deliver clinical consultations virtually.	Medical cart, all-in-one computer, PTZ and GEIS® Camera, peripherals, integrated with Visionflex software, to deliver clinical consultations virtually in healthcare setting.
\$5K-\$10K HARDWARE PER UNIT	\$10K-\$15K HARDWARE PER UNIT	\$15K-\$30K HARDWARE PER UNIT
Software licensing fee ~\$5k per annum		
Clients that have existing medical devices and require virtual clinical consultation capability in any setting.	Clients that require mobile devices to deliver virtual clinical consultations (i.e., in-home care, out-patient services, rural health care and GP clinics ).	Clients that are in physical healthcare settings that require virtual clinical consultation capabilities (i.e., hospitals, aged care and correctional facilities, rural health care and GP clinics).

# Proprietary Software (Virtual Care Platform)

A virtual healthcare platform allowing practitioners to virtually examine, diagnose, monitor, and treat patients.

## ProEX Software

Perform collaborative, clinical, evidence-based consultations between clinicians and patients in any location.



**Clinical grade consultations:** Perform in-depth clinical consultations on any internet connected device.



**Real time clinical data:** Connectivity with a multitude of peripheral diagnostic devices providing real time clinical data.



**Connect multiple cameras:** Simultaneously include feeds from multiple medical cameras within the consultation.



**Secure patient data:** Capture and securely transfer sensitive patient data of video, images and information into electronic health records.



A user-friendly video conferencing platform that delivers health services and medical expertise to patients via internet connected devices.



**Enhanced video conferencing:** Delivers diagnostic-quality video and audio, with high-speed data transmission and end-to-end encryption.



**Real time data access:** Integrates seamlessly with ProEX Software, allowing patient health data to be collected, viewed, and shared real time.







**Stethoscope audio transition:** Digitally transmits stethoscope audio unattainable through conventional video conferencing platforms due to its unique frequency type.



**Image capture and sharing:** Capture, annotate and instantly share clinical images while conducting video consultations for live discussion and collaboration.

# Revenue Model

Core Offering	<div>HARDWARE</div> <div>SOFTWARE</div>	
Key Product / Services		
Revenue Streams	<div><div>UPFRONT / ONE-OFF \$5k – \$30k per unit depending on solution</div></div>	<div><div>RECURRING REVENUE ~\$5k per annum for annual software license</div></div>
GP margin	60–65% GP margin	90–95% GP margin
Repeat Revenue	Each new software license typically sold with hardware solution	



Visionflex Group

# H1 FY25 Highlights



# H1 FY25 Financial Summary

**Note:** Presented below is the Visionflex division (including corporate costs), key financial metrics. For a detailed group statutory Profit and Loss (including businesses exited during the year), refer to the Appendix 4D & H1 FY25 Interim Financial Report – 31 December 2024

Visionflex  
Revenue

\$1.9m

↓ 42%<sup>1</sup>

Subscription Revenue  
(Software & Support)

\$0.7m

↑ 335%<sup>1</sup>

Gross  
Margin

81%

↑ Materially

Underlying  
EBITDA<sup>2</sup>

(\$1.3m)

↓ (\$1.2m)<sup>1</sup>

Current Ratio

107%

↑ 37%

Annual Recurring  
Revenue (ARR)

\$1.6m

↑ 114%<sup>1</sup>

External Debt  
(& accrued interest)

\$2.4m

↓ (\$4.0m)<sup>1</sup>

Cash

\$2.4m

↑ (\$0.6m)<sup>1</sup>

1. Comparison to prior corresponding period (H1 FY25/31 December 2023)
2. Underlying EBITDA = EBITDA excluding share-based payment and other non operating or one-off costs
3. Continuing business

# Strategy Summary and Progress in H1 FY25

## Accelerating Customer Traction

- Multiple trial sites and early penetration into new markets underpinning material future opportunity:
  - **Spark Health (NZ, subsidiary of one NZ largest telco companies):** National reseller agreement to deliver virtual care solutions in NZ; first orders delivered in November 2024.
  - **BUPA (AUS):** Expansion into the private health insurance industry with the supply Visionflex GEIS cameras to all 57 of BUPA's aged homes supporting over 5,000 residents.
  - **Kha Loc Medical (Vietnam):** a leading medical distributor in Vietnam; first units shipped in Q1 FY25 with Vietnam representing a significant new market opportunity for both hardware and software.
  - **Darling Downs Government Indigenous "Wellness Connect Initiative (AUS):** Trialling both hardware and software platform involves multiple LHD's and Aboriginal Community Controlled Health organisations to deliver new models of care.
  - **Royal Flying Doctor Service (RFDS) Victoria (AUS):** selected via a competitive tender process with initial contract for Visionflex's software platform which will sit alongside RFDS's newly announced Electronic Health Record.
  - **Anglicare (AUS):** leading Australian aged care operator with initial trial covering three sites with potential for further expansion.

## Outlook

- ARR of \$1.6m as of 31 December 2024.
- Enterprise sales opportunities moving into selection stage of the pipeline, against a backdrop of increasing referenceability.
  - Growing pipeline across several key market areas including primary health networks, hospitals, aged care and resource companies, both in Australia and overseas.
- Targeting Underlying EBITDA positive in Q4 FY25.
- \$2.4m cash and \$2.4m external debt (and accrued interest) as of 31 December 2024; sufficient capital to deliver growth objectives.



# Strategic Priorities – H2 FY25

---

## 1 Deliver profitable growth:

- Targeting to be underlying run rate EBITDA positive in Q4 FY25.
- Qualified pipeline >\$25m.

## 3 Expand on established pipeline of customers:

- Expand infrastructure with multiple government funded customers.
- Growth in other key industry verticals including:
  - aged/home care; regional primary care;
  - resources sector; indigenous health.

## 2 Transition to recurring revenue via SaaS:

- Transition to SaaS pricing delivering growth in annual recurring revenue (ARR) with 114% growth since the pcip.
- ARR of \$1.6m as of 31 December 2024.

## 4 Seize opportunities in overseas markets:

- Expand market share in New Zealand through Spark Health.
- Additional international distribution agreements are progressing with international revenue expected to increase in 2H FY25.


Visionflex Group

# H1 FY25 Financial Overview




# Financial Dashboard


Revenue  
(By Type)




Revenue  
(By Region)



ARR  
Growth



Underlying  
EBITDA



# Profit & Loss

Strong growth in recurring software licenses underpin rationale for transitioning business model and future profitability. Delayed enterprise hardware sales in H1 FY25 are expected to be secured over H2 FY25

Profit and Loss (\$'000's)		H1 FY24	H1 FY25	% Movement
Subscription (software & support)	1	157	682	335%
Hardware	2	2,928	991	(66%)
Other		165	220	33%
<b>Total Revenue</b>		<b>3,251</b>	<b>1,894</b>	<b>(42%)</b>
COGS		(1,348)	(363)	(73%)
<b>Gross profit</b>	3	<b>1,903</b>	<b>1,530</b>	<b>(20%)</b>
Gross profit margin %		58.5%	80.8%	
Staff costs	4	(1,439)	(2,104)	46%
Operating costs		(609)	(678)	11%
<b>Total Operating costs</b>		<b>(2,047)</b>	<b>(2,781)</b>	<b>36%</b>
<b>Underlying EBITDA</b>		<b>(145)</b>	<b>(1,251)</b>	<b>764%</b>
Share based payments		(314)	(246)	(22%)
Legacy Inventory Write Down		-	(252)	na
<b>EBITDA</b>		<b>(458)</b>	<b>(1,749)</b>	<b>281%</b>
Depreciation and amortisation		(6)	(31)	450%
Interest revenue		4	-	na
Finance costs	5	(410)	(155)	(62%)
<b>Profit before tax (PBT)</b>		<b>(871)</b>	<b>(1,935)</b>	<b>122%</b>

**Note:** For a detailed group statutory Profit and Loss (including exited businesses during the prior period), refer to the Appendix 4D & H1 FY25 Interim Financial Report – 31 December 2024

- 1 Strong growth in recurring subscription revenues validating progressive shift towards a sustainable ARR business.
  - Contracted ARR (31 Dec) of \$1.6m to result in further subscription revenue uplift in H2 FY25.
- 2 Delayed enterprise sales (with large hardware component) impacted hardware revenue, noting material contracts delivered in the pcip.
- 3 Gross profit margin increased to 81%, highlighting strength of business model as recurring software revenue becomes an increasingly higher percentage of total revenue.
- 4 H1 FY25 costs in line with H2 FY24 costs. Staff costs increased 46% on the pcip, reflecting investment in increased sales, marketing activity to drive new sales and customer renewals.
  - R&D costs expensed as incurred. A portion of these costs are eligible for a refundable R&D tax refund.
- 5 Finance (interest) costs reduced by 62% following debt reduction to \$2.3m (incl accrued interest).

# Balance Sheet

Material improvement in strength of balance sheet provides operating flexibility to pursue growth opportunities

Balance Sheet (\$'000's)		Jun-24	Dec-24	% Movement
Cash and cash equivalents	1	1,161	2,428	109%
Inventories		648	342	(47%)
Income tax refund	2	550	316	(42%)
Other current assets		466	451	(3%)
<b>Total current assets</b>	3	<b>2,825</b>	<b>3,537</b>	<b>25%</b>
Non-current assets		57	139	142%
<b>Total assets</b>		<b>2,882</b>	<b>3,676</b>	<b>28%</b>
Trade creditors		465	143	(69%)
Accrued expenses and other payables	4	1,505	581	(61%)
Accrued interest		441	442	0%
Borrowings	5	4	1,004	23,708%
Contract liabilities	6	1,411	1,007	(29%)
Employee provisions		184	123	(33%)
<b>Total current liabilities</b>	3	<b>4,010</b>	<b>3,301</b>	<b>(18%)</b>
Borrowings	5	6,825	1,000	(85%)
Contract liabilities	6	144	57	(60%)
Employee provisions		10	14	44%
<b>Total liabilities</b>		<b>10,989</b>	<b>4,373</b>	<b>(60%)</b>
<b>Net Assets</b>		<b>(8,107)</b>	<b>(697)</b>	<b>(91%)</b>

- 1 \$2.4m cash provides sufficient headroom to deliver growth objectives and reach run rate EBITDA positivity in Q4 FY25.
- 2 Income tax refund (R&D tax receivable forecast to be received in Q2 FY26.
- 3 Improvement in the current ratio from 70% to 107% highlighting the improvement in the strength of the balance sheet.
- 4 30 June 2024 balance included a number of annual accruals which were paid during H1 FY25.
- 5 Material reduction in external debt which was reduced as part of the capital raise process completed in July-24. Variation Agreement signed 20 February 2025 to extend the repayment date of convertible notes until at least March 2026.
- 6 Contract liabilities relates to unearned revenue for which the related service has yet to be delivered.



# Cash Flow Statement

Near term operating cashflow driven by large enterprise hardware contracts, however over time recurring software revenue will underpin a stabilisation in operating cashflows

Cash Flow Statement (\$000)	H1 FY24	H1 FY25	% Movement
Receipts from customers	1 5,748	1,589	(72%)
Payments to suppliers and employees	(6,180)	(4,171)	(33%)
Interest received	4	-	(100%)
Interest and other finance costs paid	2 (383)	(31)	(92%)
Research and development tax credit	635	480	(24%)
<b>Net cash used in operating activities</b>	<b>(177)</b>	<b>(2,133)</b>	<b>1,103%</b>
Payment for PP&E	(4)	(23)	491%
Payments for intangibles	(1)	-	(100%)
Proceeds from disposal of business	300	-	(100%)
<b>Net cash from/(used in) investing activities</b>	<b>295</b>	<b>(23)</b>	<b>(108%)</b>
Net proceeds from issue of shares	(6)	2,424	(41,628%)
Proceeds from convertible notes facility	3 200	1,000	400%
<b>Net cash from financing activities</b>	<b>194</b>	<b>3,424</b>	<b>1,663%</b>
<b>Cash and equivalents at the beginning of period</b>	<b>1,443</b>	<b>1,161</b>	<b>(20%)</b>
Net increase in cash and equivalents	312	1,267	306%
<b>Cash and cash equivalents at the end of period</b>	<b>1,755</b>	<b>2,428</b>	<b>38%</b>

- 1 Decline in customer receipts in-line with corresponding reduction in revenue and delayed enterprise sales.
- 2 Decrease in interest costs driven by material reduction in external debt.
- 3 Funding of \$1.0m over the course of Q2 FY25 in-line with current terms convertible note facility provided by two major shareholders.

Visionflex Group

# Market Segments



# Key customers by market segment



## PRIMARY HEALTH NETWORKS



## AGED CARE



## CORPORATES



## LOCAL HEALTH DISTRICTS



## INDIGENOUS HEALTH & OTHER HEALTH BODIES



## INTERNATIONAL



# Expansion in key market segments



## INDIGENOUS HEALTH

- NACCHO is the national peak body representing 145 Aboriginal Health Organisations delivering healthcare to First Nations people right across the country.<sup>1</sup>
- Government funding of over circa \$1B per annum.<sup>2</sup>
- Visionflex collaborates with 20+ organisations in the Indigenous Health sector fostering impactful healthcare solutions.

## AGED/HOME CARE

- Residential Aged Care: There are 886 organisations operating 2,695 residential aged care services as at 30 June 2018.<sup>3</sup>
- Home Care Services: There are 873 organisations operating 2,599 home care services as at 30 June 2018.<sup>3</sup>
- Home Support Outlets: 1,456 organization's operating 3,542 home support outlets as at 30 June 2018.<sup>3</sup>
- The aged care sector received \$2.2bn in Australian government funding in 2024-2025.<sup>5</sup>

## RESOURCE SECTOR

- Global operations in remote and challenging environments where workforce health and well-being is critical to operations.<sup>6</sup>
- Significant employee healthcare management programs in place to manage staff health & productivity and costly evacuations.
- After successful trials with ExxonMobil, virtual care services were implemented across Melbourne, the Longford Gas Plant, and offshore platforms in Bass Strait.

## CORRECTIONAL FACILITIES

- There are 116 custodial correctional facilities across Australia<sup>4</sup> which ensure that inmates are supervised and managed in a secure, safe and humane manner.<sup>4</sup>
- Correctional facilities are often located in remote areas, with reduced access to hospitals, physicians and medical personnel.
- Justice Health is a key customer of Visionflex.

1. <https://www.naccho.org.au/>, accessed on 30 May 2024

2. Based on 2022-2023 budgeted levels, see <https://www.health.gov.au/sites/default/files>, accessed on 30 May 2024


3. [https://www.apoh.gov.au/About\\_Parliament](https://www.apoh.gov.au/About_Parliament), based on service levels in 2018-2019, accessed on 30 May 2024

4. <https://www.aihw.gov.au/reports/australias-welfare/adults-in-prison>, accessed 30 May 2024

5. <https://www.health.gov.au/sites/default/files/2024-05/budget-2024-25-quality-aged-care.pdf>, accessed on 30 May 2024

6. <https://maintenanceandcare.com/maritime-blog/>, accessed on 30 May 2024.

# International expansion



Visionflex products sold to all key global jurisdictions – Americas, Europe and Asia.

\$0.3m of sales to customers in 6 overseas countries in 1H FY25.

Growth opportunities through strategic distribution partnerships expected to accelerate in 2H FY25.



# Important notices

This H1 FY25 Results Investor Presentation (Presentation) has been prepared by Visionflex Group Limited ACN 138 897 533 (ASX:VFX) (**Company**) & is dated **21 February 2025**.

## Acceptance

The information in this Presentation remains subject to change without notice. By accepting this Presentation, you agree to be bound by the following limitations and conditions.

## Summary information

This Presentation contains summary information about the Company, its subsidiaries and their activities which is current as at the date of this Presentation (unless otherwise noted) and the information in this Presentation remains subject to change without notice. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the *Corporations Act 2001 (Cth)* or the securities laws of any other jurisdiction.

This Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged on the Australian Securities Exchange (ASX) which are available at [www.asx.com.au](http://www.asx.com.au) or [www.visionflex.com.au](http://www.visionflex.com.au).

## Not an offer

This Presentation is not a prospectus, product disclosure document or other offering document in relation to securities under Australian law. It has not been and will not be filed with or approved by any regulatory authority in Australia, including the Australian Securities and Investments Commission (ASIC), or any other jurisdiction. This Presentation does not constitute and should not be considered as an offer, invitation or recommendation to subscribe for or purchase any security in the Company in any jurisdiction. The distribution of this document in jurisdictions outside Australia may be restricted by law. If you are outside Australia, you may not be a person to whom an offer of securities in the Company may lawfully be made under the applicable laws in the jurisdiction in which you are situated without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. Any such restrictions should be observed.

## Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire any securities in the Company. Neither this Presentation nor anything contained in it forms the basis of any contract or commitment and no agreement to subscribe for securities will be entered into on the basis of this Presentation. This Presentation does not take into account any recipient's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in the Company is considered speculative in nature and is subject to known and unknown risks, some of which are beyond the control of the Company. Before making any investment decision in connection with the acquisition of securities in the Company, investors should consult their own legal, tax, and/or financial advisers in relation to the information in, and action taken on the basis of, this Presentation and the Company more generally. The Company does not guarantee any particular rate of return or the performance of the Company, or the repayment of capital and nor does it guarantee any particular tax treatment.

## Financial information

The historical financial information in this Presentation is, or is based upon, information that has been lodged with the Australian Securities Exchange (ASX). This Presentation should be read in conjunction with the Company's Preliminary Financial Report – 30 June 2024 and its accompanying notes.

In this Presentation, all dollar values are in Australian dollars (A\$), unless otherwise stated.

A number of figures, amounts, percentages, estimates, calculations of values and fractions in this Presentation are subject to the effect of

rounding. Accordingly, the actual calculations of these figures may differ from the figures set out in this Presentation.

## Past performance

Statements about past performance in this presentation is given for illustrative purposes only and cannot be relied upon as an indicator of, and provides no guidance as to, future performance of the Company.

## Forward-looking statements

This Presentation may contain certain forward-looking statements and comments about future events, including the outcome and effects. Forward-looking statements can generally be identified by the use of words such as 'project', 'foresee', 'plan', 'expect', 'aim', 'intend', 'anticipate', 'believe', 'estimate', 'may', 'should', 'will' or similar expressions. Forward-looking statements involve known and unknown risks, significant uncertainties, assumptions, contingencies, and other factors, many of which are outside the control of the Company, are subject to change without notice, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and which may cause the actual results or performance of the Company to be materially different from any results or performance expressed or implied by such forward-looking statements. Such forward-looking statements speak only as of the date of this Presentation. Forward looking statements should not be relied on as an indication or guarantee of future performance.

No representation, warranty or undertaking is made that any projection, forecast, assumption or estimate contained in this Presentation should or will be achieved. Recipients of this Presentation must conduct their own independent investigation, evaluation and analysis of the matters and data set out in this Presentation and other publicly available information about the Company, and rely entirely on such investigation and analysis.

## Disclaimer

To the maximum extent permitted by law, no representation, warranty or undertaking (express or implied) is made, and no responsibility is accepted by the Company or any of its affiliates, related bodies corporate, partners, shareholders, directors, officers, employees, representatives, consultants or advisers or any other person (Parties) as to the adequacy, accuracy, completeness or reasonableness of any statement or any of the information contained in or referred to in this Presentation or as to any other related matter. To the maximum extent permitted by law, none of the Parties takes any responsibility for any loss, damage or cost suffered as a result of any inadequacy, incompleteness or inaccuracy in any such statement or information.

Except as required by law or regulation (including the ASX Listing Rules), the Company does not undertake to provide any additional or updated information, whether as a result of new information, future events, results or otherwise, in relation to any information in this Presentation, including any forward-looking statement.

To the maximum extent permitted by law, the Parties do not accept any liability to any person for any direct, indirect or consequential loss, damage or cost arising from the use of this material. This Presentation is not a recommendation by any of the Parties that any recipient invest in the Company.

## Photographs and Diagrams

Photographs used in this Presentation which do not have descriptions are for illustration only and should not be interpreted to mean that any person shown endorses this Presentation or its contents or that the assets shown in them are owned by the Company. The photographs contained in this Presentation are the property of or are licensed to the Company and are protected under copyright laws. No permission is granted for the reproduction of these photographs outside of their appearance in this Presentation. Diagrams in this Presentation have been prepared by the Company and are illustrative only and may not be drawn to scale. Unless otherwise stated, all data contained in charts, graphs and tables is based on information available at the date of this Presentation.

# Visionflex Group

Visionflex Group Limited  
Unit 1, 8 Prosperity Parade,  
Warriewood NSW 2102

[VFX-GROUP.COM](http://VFX-GROUP.COM)

---

Joshua Munday

CHIEF EXECUTIVE OFFICER

E: [jmunday@visionflex.com](mailto:jmunday@visionflex.com)

